You are here: Industry Insights > Johnson & Johnson

News List

Winners of the first Asia-proper Johnson & Johnson Innovation, JLABS Singapore Quickfire Challenge a pharmaasia
September 20, 2017
Winners of the first Asia-proper Johnson & Johnson Innovation, JLABS Singapore Quickfire Challenge were announced at the Ecosystem Day @ SWITCH.
Johnson & Johnson announces collaboration with U.S. Department of Health and Human Services to fight worldpharmanews
September 19, 2017
Johnson & Johnson (NYSE: JNJ) announced that Janssen is working with the US Department of Health and Human Services's Office of Preparedness and Response Assistant Secretary (ASPR)
J&J backs out of $1.1 billion hep C deal, wiping 22.2% from Achillion's stock pharmafile
September 13, 2017
Johnson & Johnson has announced that it is to back out of a $1.1 billion deal with Achillion Pharmaceuticals to develop the firm’s hepatitis C drug pipeline. The news sent Achillion’s stock reeling, wiping away 22.2% of its value.
ESC: J&J's Xarelto combo tops aspirin in artery disease, cueing $1.5B in U.S. sales fiercepharma
August 29, 2017
New data for J&J's Xarelto could widen the med's patient population by more than 50%, Credit Suisse's Vamil Divan predicts.
Protagonist Announces Closing of Janssen License, Collaboration Agreement for PTG-200 americanpharmaceuticalreview
August 28, 2017
Protagonist Therapeutics has closed the worldwide license and collaboration transaction for PTG-200 with Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson
Johnson & Johnson objects to a Janssen-developed drug's use in executions fiercepharma
August 23, 2017
As drugmakers have put contract restrictions on use of their drugs for executions, the half-dozen states that use lethal injection are finding it more difficult to secure supplies.
Johnson & Johnson hit with $417M verdict as talcum powder liability losses mount fiercepharma
August 23, 2017
J&J says it will appeal its latest loss in a case tying its baby powder to ovarian cancer, even as 4,800 more cases are pending.
Johnson & Johnson partners with CSIR-IMTECH to develop new tuberculosis treatments pharmaasia
August 21, 2017
MOU aims to increase level and accelerate pace of innovation needed to make tuberculosis history
Big Pharma ally Atreca scoops $35M as I-O assets near IND fiercebiotech
August 18, 2017
Atreca plans to pick a clinical candidate by the end of the year.
Johnson & Johnson in partnership with CSIR-IMTECH expressbpd
August 17, 2017
To develop innovative new tuberculosis treatments

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page